Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores

Heart

Volumn 100, Issue 19, 2014, Pages 1524-1530

  Mitchell, L Brent ^a   Southern, Danielle A ^a   Galbraith, Diane ^a   Ghali, William A ^a   Knudtson, Merril ^a   Wilton, Stephen B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; AGE; AGED; CANADA; COMORBIDITY; COMPLICATION; DECISION SUPPORT SYSTEM; DIABETES MELLITUS; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC ATTACK, TRANSIENT; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PROCEDURES; PROPENSITY SCORE; RISK ASSESSMENT; SEX DIFFERENCE; STANDARDS; STROKE;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; CANADA; COMORBIDITY; DECISION SUPPORT TECHNIQUES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; RESEARCH DESIGN; RISK ASSESSMENT; SEX FACTORS; STROKE;

EID: 84900883953     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-305303     Document Type: Article

References (29)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 Update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
2. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation∗: American college of chest physicians evidence-based clinical practice guidelines (8th edition). CHEST J 2008;133(6-suppl):546S-92S.
3. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
4. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
5. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500-10.
6. Henriksson KM, Farahmand B, Johansson S, et al. Survival after stroke - the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 2010;141:18-23.
7. Chao TF, Liu CJ, Chen SJ, et al. CHADS(2) score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol 2013;168:1360-3.
8. Biancari F, Asim Mahar MA, Kangasniemi OP. CHADS(2) and CHA(2)DS(2)-VASc Scores for Prediction of Immediate and Late Stroke after Coronary Artery Bypass Graft Surgery. J Stroke Cerebrovasc Dis 2013;22:1304-11.
9. Hornero F, Martin E, Paredes F, et al. Stroke after coronary artery bypass grafting: preoperative predictive accuracies of CHADS2 and CHA2DS2VASc stroke risk stratification schemes. J Thorac Cardiovasc Surg 2012;144:1428-35.
10. Lip GY, Lin HJ, Chien KL, et al. Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol 2013;168:414-9.
11. Welles CC, Whooley MA, Na B, et al. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. Am Heart J 2011;162:555-61.
12. Poc¸i D, Hartford M, Karlsson T, et al. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest 2012;141:1431-40.
13. Southern DA, Norris CM, Quan H, et al. An administrative data merging solution for dealing with missing data in a clinical registry: adaptation from ICD-9 to ICD-10. BMC Med Res Methodol 2008;8:1.
14. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2005;36:1776-81.
15. Keogh C, Wallace E, Dillon C, et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011;106:528-38.
16. Ntaios G, Lip GY, Makaritsis K, et al. CHADS(2), CHA(2)S(2)DS(2)-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013;80:1009-17.
17. Stollberger C, Wegner C, Finsterer J. CHADS(2)- and CHA(2)DS(2)VASc Scores and Embolic Risk in Left Ventricular Hypertrabeculation/Noncompaction. J Stroke Cerebrovasc Dis 2013;22:709-12.
18. Ohira T, Shahar E, Chambless LE, et al. Risk factors for ischemic stroke subtypes. Stroke 2006;37:2493-98.
19. Kim YD, Cha MJ, Kim J, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke 2011;42:930-4.
20. Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074-80.
21. Cha MJ, Kim YD, Nam HS, et al. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2 DS2-VASc scores. Eur J Neurol 2012;19:473-9.
22. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739-45.
23. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-29.
24. Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus sspirin after myocardial Infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-50.
25. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-89.
26. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
27. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
28. Fitzmaurice DA, Hobbs FDR, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383.
29. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb. Haemost 2013;110:213-22.